NANOBIOTIX Provides Q1 2024 Operating and Financial Update

Nanobiotix SA

PARIS and CAMBRIDGE, Massachusetts, May 22, 2024 (GLOBE NEWSWIRE) – NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ”Company”), an advanced clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for cancer patients, today provided an update on operational progress and reported financial results for the first quarter of 2024.

First Quarter Financial Updates

Cash and cash equivalents:

Based on the current operating plan and financial projections, Nanobiotix anticipates that cash and cash equivalents of €58.9 million as of March 31, 2024 will fund its operations in the third quarter of 2025, which includes the milestone of U.S. $20 million which we have received in the meantime.

Teleconference and Webcast

Nanobiotix will host a conference call and live audio webcast today, on Wednesday, May 22, 2024, at 8am EDT/2pm CEST, before the US market opens. During the conference call, Laurent Levy, CEO, will provide an update on business activities before answering questions from attendees.

Call details are as follows:

Audio-only dial-in link: Click here

Stream link: Click here

Attendees may use the audio-only link above to register and obtain dial-in instructions to listen to the telephone presentation and ask questions during the Q&A session, or participants may use the webcast link to register, listen, and watch the slideshow online; the replay version will be available at the same link as the webcast shortly after the presentation and will be archived on the Company’s website at www.nanobiotix.com. It is recommended to join 10 minutes before the start of the event. Participants are invited to email their questions in advance to investors@nanobiotix.com.

About NANOBIOTIX

Nanobiotix is ​​a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference to humanity. The Company’s philosophy is rooted in the concept of pushing the limits of what is known to expand the possibilities for human life.

Incorporated in 2003, Nanobiotix is ​​headquartered in Paris, France and has been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The company has subsidiaries in Cambridge, Massachusetts (United States), among other locations.

Nanobiotix owns more than 25 families of patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) central nervous system disorders.

The story continues

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn It is Twitter.

Disclaimer

This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of products arising therefrom and the period of time through which the Company anticipates that its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “may”, “could”, “might”, “might”, “plans”, “potential”, “should” and “will” or the negative of these and similar expressions are intended identify forward-looking statements. These forward-looking statements, which are based on our management’s current expectations and assumptions and information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those implied by the forward-looking statements, including risks relating to Nanobiotix’s business and financial performance, which include the risk that underlying assumptions the Company’s cash runway projections do not materialize. More information about risk factors that could affect the company’s business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on April 24, 2024 under “Item 3.D. Risk Factors,” in Nanobiotix’s 2023 universal registration document filed with the AMF on April 24, 2024, and in subsequent filings that Nanobiotix makes with the SEC from time to time, which are available on the SEC’s website at www. sec.gov. The forward-looking statements included in this press release speak only as of the date of this press release and, except as required by law, Nanobiotix undertakes no obligation to publicly update these forward-looking statements.

Contacts

Attachment

Source